Výsledky vyhledávání - "Samir E. Witta"

Data from Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines

Autor: Paul A. Bunn, Mark W. Geraci, Fred R. Hirsch, Wilbur A. Franklin, Anna Barón, Chan Zeng, Razvan Lapadat, Michio Sugita, Samir E. Witta, Barbara A. Helfrich, Christopher D. Coldren

Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) produce objective responses in a minority of patients with advanced-stage non–small cell lung cancer (NSCLC), and about half of all treated patients progress within 6 w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::112ce840588081f9340ec2546303707a
https://doi.org/10.1158/1541-7786.c.6542668

Zobrazit plný text záznamu

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Autor: Samir E. Witta, Alexander I. Spira, Fred R. Hirsch, Marcus A. Neubauer, Marileila Varella-Garcia, Paul A. Bunn, Katrik Konduri, Robert L. Ruxer, Robert M. Jotte

Publikováno v: Journal of Clinical Oncology. 30:2248-2255

Purpose Histone deacetylase inhibitors (HDACis) have been shown to overcome resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to epigenetic changes and epithelial-mesenchymal transition (EMT) state. This ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b937954f20d7fc46665e0c1cb869c8f2
https://doi.org/10.1200/jco.2011.38.9411

Zobrazit plný text záznamu

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

Autor: Michele Basche, Michael Kangas, Kaye L. Roberts, R. S. Addison, Brian R. Creese, Mark Morrow, S. Gail Eckhardt, Lia Gore, Cindy L. O'Bryant, Samir E. Witta, Daniel L. Gustafson, Scott N. Holden, Mary Kay Schultz, Kat Davis, Jane C. Moore, Thu Suong T. Nguyen, Adrah Levin

Publikováno v: Clinical Cancer Research. 12:5471-5480

Purpose: PI-88 is a mixture of highly sulfated oligosaccharides that inhibits heparanase, an extracellular matrix endoglycosidase, and the binding of angiogenic growth factors to heparan sulfate. This agent showed potent inhibition of placental blood

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::209fdf9b46efd2811b12729be5fbe5be
https://doi.org/10.1158/1078-0432.ccr-05-2423

Zobrazit plný text záznamu

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Autor: Marileila Varella-Garcia, Paul A. Bunn, Wilbur A. Franklin, Rafal Dziadziuszko, Karen Kelly, Samir E. Witta, Fred R. Hirsch

Publikováno v: Clinical Cancer Research. 12:3652-3656

The selection of patients for tumor-specific therapies using molecular/biological properties of the patient's tumor has been a long tradition in breast cancer (e.g., estrogen receptor, progesterone receptor, and HER-2/ neu ) but has not been widely a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e303b8f6afd89e03136a7816dc11bc8
https://doi.org/10.1158/1078-0432.ccr-06-0261

Zobrazit plný text záznamu

Characterization of the Bex gene family in humans, mice, and rats

Autor: Enrique Alvarez, Curt R. Freed, Samir E. Witta, Wenbo Zhou

Publikováno v: Gene. 357:18-28

To better understand the development of ventral mesencephalic dopamine neurons, we performed subtractive hybridization screens to find ventral mesencephalic genes expressed at rat embryonic day 10 when these neurons begin to differentiate. The most c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d882ec3315dfa3b4328c84d00b9887c5
https://doi.org/10.1016/j.gene.2005.05.012

Zobrazit plný text záznamu

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

Publikováno v: JNCI: Journal of the National Cancer Institute. 97:643-655

Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). We carried out a clinical study to compare the relationship be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a45714cdbfd5785993105b6f0db8ef9e
https://doi.org/10.1093/jnci/dji112

Zobrazit plný text záznamu

Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer

Autor: Fred R. Hirsch, Samir E. Witta

Publikováno v: Current Opinion in Oncology. 17:118-122

PURPOSE OF REVIEW Epidermal growth factor receptor (EGFR) Inhibitors have shown promising results in patients with advanced non-small cell lung cancers (NSCLC) who previously have failed on chemotherapy. Objective response is achieved in 10 to 28% of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de17818736f6128f3b52ce728f76c40f
https://doi.org/10.1097/01.cco.0000155059.39733.9d

Zobrazit plný text záznamu

A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors

Autor: Karen Kelly, Martha Persky, Samir E. Witta, Alexander Menter, Amy Gibbs, A. Scott Pierson, Scott N. Holden, Patrick Pallansch, Paul A. Bunn, S. Gail Eckhardt, Daniel C. Chan, Chan Zeng, Michael E. Long, Anna E. Barón, Daniel L. Gustafson, Cindy L. O'Bryant, Michele Basche

Publikováno v: Clinical Cancer Research. 10:7229-7237

Purpose: Exisulind (sulindac sulfone, FGN-1, Aptosyn) is a sulindac metabolite that induces apoptosis via inhibition of cyclic GMP-phosphodiesterase. This agent demonstrated tumor growth inhibition in rodent models of colon, breast, prostate, and lun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4cbddc4457c62d141644289af4aceb8
https://doi.org/10.1158/1078-0432.ccr-03-0181

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání